Stereoselective Metabolic Disposition of Enantiomers of Ofloxacin in Rats

References

• Affolter H., Hertel C., Jaeggi K., Portenier M., Staehelin M. (‐)‐S‐‘3H’CGP‐12177 and its use to determine the rate constants of unlabeled β‐adrenergic antagonists. Proceedings of the National Academy of Sciences 1985; 82: 925–929
   PubMed Web of Science ®Google Scholar
• Bai S. A., Wilson M. J., Walle U. K., Walle T. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. Journal of Pharmacology and Experimental Therapeutics 1983; 227: 360–364
   PubMed Web of Science ®Google Scholar
• Bailey J. M. G., Heppleston C., Richmond S. J. Comparison of the in vitro activities of ofloxacin and tetracycline against Chiamydia trachomatis as assessed by indirect immunofluorescence. Antimicrobial Agents and Chemotherapy 1984; 26: 13–16
   PubMed Web of Science ®Google Scholar
• Borner K., Lode H. Biotransformation von ausgewählten Gyrasehemmern. Infection 1984; 14(Suppl. 1)54–59
   Google Scholar
• Brown N. A., Jahnchen E., Mulles W. E., Wollert U. Optical studies on the mechanism of the interaction on the enantiomers of the anticoagulant drugs phenprocoumon and warfarin with human serum albumin. Molecular Pharmacology 1977; 13: 70–79
   PubMed Web of Science ®Google Scholar
• Buckpitt A. R., Castagnoli N., Jr., Nelson S. D., Jones A. D., Bahnson L. S. Stereoselectivity of naphthalene epoxidation by mouse, rat, and hamster pulmonary, hepatic, and renal microsomal enzymes. Drug Metabolism and Disposition 1987; 15: 491–498
   PubMed Web of Science ®Google Scholar
• Fujii T., Furukawa H., Yoshida K., Miyazaki H., Hashimoto M. Disposition and metabolism of ‘14C’AT‐2266, I. Single administration. Chemotherapy, Tokyo 1984; 32(Suppl. 3)117–135
   Google Scholar
• Hayakawa I., Atarashi S., Yokohama S., Imamura M., Sakano K., Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrobial Agents and Chemotherapy 1986; 29: 163–164
   PubMed Web of Science ®Google Scholar
• Küpfer A., Desmond P. V., Schenker S., Branch R. A. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. Journal of Pharmacology and Experimental Therapeutics 1982; 221: 590–597
   PubMed Web of Science ®Google Scholar
• Lefkowitz R. J., Williams L. T. Catecholamine binding to the β‐adrenergic receptor. Proceedings of the National Academy of Sciences 1977; 74: 515–519
   PubMed Web of Science ®Google Scholar
• Lennard M. S., Tucker G. T., Silas J. H., Freestone S., Lamsey L. E., Woods H. F. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clinical Pharmacology and Therapeutics 1983; 34: 732–737
   PubMed Web of Science ®Google Scholar
• Mayer J. M., Bartolucci C., Maitre J. M., Testa B. Metabolic chiral inversion of antiinflammatory 2‐arylpropionates: lack of reaction in liver homogenates, and study of methine proton acidity. Xenobiotica 1988; 18(5)533–543
   PubMed Web of Science ®Google Scholar
• Okazaki O., Kurata T., Hashimoto K., Sudo K., Tsumura M., Tachizawa H. Metabolic disposition of DL‐8280. The second report: absorption, distribution and excretion of 14C‐DL‐8280 in various animal species. Chemotherapy, Tokyo 1984; 32(Suppl. 1)1185–1202
   Google Scholar
• Osada Y., Ogawa H. Antimycoplasmal activity of ofloxacin (DL‐8280). Antimicrobial Agents and Chemotherapy 1983; 23: 509–511
   PubMed Web of Science ®Google Scholar
• Sato K., Matsuura Y., Inoue M., Une T., Osada Y., Ogawa H., Mitsuhashi M. In vitro and in vivo activity of DL‐8280, a new oxazine derivative. Antimicrobial Agents and Chemotherapy 1982; 22: 548–553
   PubMed Web of Science ®Google Scholar
• Silber B., Holford N. H. G., Riegelman S. Stereoselective disposition and glucuroni‐dation of propranolol in human. Journal of Pharmaceutical Sciences 1982; 71: 699–703
   PubMed Web of Science ®Google Scholar
• Sudo K., Okazaki O., Tsumura M., Tachizawa H. Isolation and identification of metabolites of ofloxacin in rats, dogs and monkeys. Xenobiotica 1986; 16: 725–732
   PubMed Web of Science ®Google Scholar
• Sudo K., Hashimoto K., Kurata T., Okazaki O., Tsumura M., Tachizawa H. Metabolic disposition of DL‐8280. The third report: metabolism of 14C‐DL‐8280 in various animal species. Chemotherapy, Tokyo 1984; 32(Suppl. 1)1203–1210
   Google Scholar
• Sugeno K., Okabe H., Norikura R., Koike M., Kawamoto K. Absorption, distribution, metabolism and excretion of cinoxacin. The second report: comparative metabolism and disposition of cinoxacin in dog, rhesus monkey, rabbit and guinea pig. Chemotherapy, Tokyo 1980; 28(Suppl. 4)90–103
   Google Scholar
• Vermeulen N. P. E. Stereoselectivity in the enzymatic biotransformation of drugs and other xenobiotics. Drug Metabolism‐From Microbes to Man, D. Benford, J. W. Bridges, G. G. Gibson. Taylor & Francis, London 1987; 615–640
   Google Scholar
• Wade D. N., Mearrick P. T., Morris J. L. Active transport of L‐dopa in the intestine. Nature 1973; 242: 463–465
   PubMed Web of Science ®Google Scholar
• Walle T. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium‐labeled pseudoracemates. Drug Metabolism and Disposition 1985; 13: 279–282
   PubMed Web of Science ®Google Scholar
• Walle U. K., Walle T., Bai S. A. Stereoselective binding of propranolol to human plasma, alpha1‐acid glycoprotein, and albumin. Clinical Pharmacology and Therapeutics 1983; 34: 718–723
   PubMed Web of Science ®Google Scholar
• Weiland G. A., Oswald R. E. The mechanism of binding of dihydropyridine calcium channel blockers to rat brain membranes. Journal of Biological Chemistry 1985; 260: 8456–8464
   PubMed Web of Science ®Google Scholar
• Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacology and Dynamics 1981; 4: 879–885
   PubMedGoogle Scholar